As always some very rational thoughts Wasa, though tend to discount letting the ship sink, especially given the market space being somewhat hot right now. Perhaps there is at least 1 other option - quick survival CR (yep, will hurt) followed some time later by bringing in some synergistic / symbiotic product already in development on some sort of deal to keep the cash price down - still involves dilution but would regenerate the business. Lots of similar examples in the past !
Disregarding miracles, suggest the upside is still down the darkened tunnel someways away. Tough game for the LTH's but still of interest to treat as a new investment. GLTAH
Ann: Anagrelide Cancer Patent For Japan, page-10
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $163.0M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 15.8¢ | 15.0¢ | $198.5K | 1.280M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 438029 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 283200 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |